NovoCure (NVCR) Accumulated Expenses (2014 - 2020)

NovoCure (NVCR) has reported Accumulated Expenses for 7 consecutive years, with $60.0 million the latest figure, recorded in Q4 2020.

• Quarterly Accumulated Expenses rose 21.42% year-over-year to $60.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $60.0 million (up 21.42% YoY) and the FY2020 annual result came in at $60.0 million, up 21.42% from the prior year.
• Accumulated Expenses rose to $60.0 million in Q4 2020 per NVCR's latest filing, from $49.4 million in the prior quarter.
• Over the last five years, Accumulated Expenses for NVCR reached as high as $60.0 million in Q4 2020 and fell as low as $10.8 million in Q1 2016.
• A 5-year average of $27.2 million and a median of $25.1 million in 2018 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2017 — Accumulated Expenses jumped 85.51% — and 2018, when it grew 4.44%.
• Year by year, Accumulated Expenses stood at $18.5 million in 2016, then jumped by 78.11% to $33.0 million in 2017, then grew by 14.72% to $37.9 million in 2018, then jumped by 30.47% to $49.4 million in 2019, then increased by 21.42% to $60.0 million in 2020.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $60.0 million, $49.4 million, and $37.9 million for Q4 2020, Q4 2019, and Q4 2018 respectively.